Selecta is backed by top-tier venture investors, including Polaris Venture Partners, Flagship Ventures, OrbiMed Advisors, NanoDimension, and Leukon Investments. Each of Selecta's investors bring a strong base of experience to support the company's growth and development.
Flagship Ventures is a venture capital firm focused on creating, financing, and building innovative companies. Founded in 1999, Flagship manages over $500 million in early-stage funds and operates from its offices at Kendall Square in Cambridge, MA. With an active portfolio of over 40 companies, the firm's strategy is to balance its investments across three principal business sectors: Therapeutics, Life Science Tools & Diagnostics, and BioEnergy/Cleantech. During the past two decades, Flagship's principals have been involved as founders or investors in many highly successful ventures including: Adnexus Therapeutics, Alere Medical, Aspect Medical, Celera Genomics, ChemGenics Pharmaceuticals, Color Kinetics, Cytyc, DataSage, Exact Sciences, Helicos Biosciences, Hypnion, IDEXX, Morphotek, PerSeptive Biosystems, and TripAdvisor. For more information, please visit www.flagshipventures.com.
NanoDimension is a venture capital firm committed to building companies developing market disruptive technologies on the nano-scale. Founded in 2002, and with offices in Europe and the United States, NanoDimension focuses on early to mid-stage investments across business sectors. For more information, please visit www.nanodimension.com.
OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector. With $7 billion in assets under management, OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed's team manages a series of private equity funds, public equity funds, royalty and debt funds, and other investment vehicles. For more information, please visit www.orbimed.com.
Established in 1996, with offices in Waltham and Seattle, Polaris has over $3 billion under management. Polaris Venture Partners has helped build numerous market leading companies, including Acceleron Pharma, Accordant Health Services, Advanced Inhalation Research, Akamai Technologies, Allaire, Alnylam Pharmaceuticals, American Superconductor, Aspect Medical Systems, Avici Systems, Centra Software, Classifieds2000, deCODE genetics, Exchange.com, Matrics, Microbia, Momenta Pharmaceuticals, Paradigm Genetics, Powersoft, PSCI, SolidWorks, and TransForm Pharmaceuticals. More information about Polaris Venture Partners is available at www.polarisventures.com.
RUSNANO was established in March 2011 as an open joint stock company created through reorganization of the state corporation Russian Corporation of Nanotechnologies. RUSNANO's mission is to develop the Russian nanotechnology industry through co-investment in nanotechnology projects with substantial economic potential or social benefit. The Government of the Russian Federation owns 100 percent of the shares in RUSNANO. Anatoly Chubais is CEO and chairman of the Executive Board of RUSNANO. Work to establish nanotechnology infrastructure and training for nanotechnology specialists, formerly conducted by the Russian Corporation of Nanotechnologies, has been entrusted to the Fund for Infrastructure and Educational Programs, a non-commercial fund also established through reorganization of the Russian Corporation of Nanotechnologies. More information about RUSNANO may be found at www.rusnano.com.